Company Snapshot

Investment Thesis

Intuitive Surgical develops robotic-assisted surgical systems and consumables that enhance minimally invasive procedures, anchored by the da Vinci and Ion platforms.

  • Installed Base Growth: The global da Vinci installed base continues to expand double digits, unlocking recurring instrument and service revenue.
  • Procedure Expansion: Urology, gynecology, general surgery, and thoracic procedures increasingly adopt robotics due to improved outcomes.
  • Ion Lung Platform: Ion extends Intuitive into diagnostic and therapeutic lung procedures with strong hospital interest.

Operating Metrics

Installed Systems 8,800+ da Vinci systems deployed worldwide
Procedure Growth Procedure volumes continue to grow in the mid-teens annually
Recurring Revenue Instruments, accessories, and services represent roughly 80% of revenue
Training Ecosystem Comprehensive education and simulation programs support surgeon adoption

Metrics reflect Intuitive Surgical Q2 2024 disclosures.

Recent Performance

MTD +0.68%
QTD +22.80%
YTD +2.65%
5Y +127.39%

The stock remains resilient as recurring revenue mix, new procedure adoption, and next-generation platforms support durable double-digit growth.

Strategic Insights

Value-Based Outcomes

Robotic-assisted surgery reduces complications, hospital stays, and readmissions, appealing to value-based care systems.

Procedure Innovation

Flexible instrumentation and digital tools expand robotics into more general surgery and lung indications.

Ecosystem Advantage

Intuitive's global service network, training, and analytics create high switching costs for hospitals.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...